US Patent Issued to Novartis on Nov. 11 for "Methods of treating inflammatory arthritis using secukinumab" (Swiss Inventors)

ALEXANDRIA, Va., Nov. 11 -- United States Patent no. 12,465,635, issued on Nov. 11, was assigned to Novartis AG (Basel, Switzerland).

"Methods of treating inflammatory arthritis using secukinumab" was invented by Shephard Mpofu (Oberwil, Switzerland), Hanno Richards (Therwil, Switzerland), Karthinathan Thangavelu (Geneva) and Matthias Machacek (Allschwil, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinum...